Compare MEI & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEI | LRMR |
|---|---|---|
| Founded | 1946 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 312.7M | 280.0M |
| IPO Year | 1994 | 2014 |
| Metric | MEI | LRMR |
|---|---|---|
| Price | $8.50 | $5.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $11.50 | ★ $16.14 |
| AVG Volume (30 Days) | 339.5K | ★ 5.8M |
| Earning Date | 03-05-2026 | 04-14-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | ★ 49.14 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $908,300,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.66 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 11.24 | N/A |
| 52 Week Low | $5.08 | $1.61 |
| 52 Week High | $10.97 | $6.42 |
| Indicator | MEI | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 51.32 | 69.16 |
| Support Level | $8.42 | $3.22 |
| Resistance Level | $8.61 | $5.37 |
| Average True Range (ATR) | 0.41 | 0.44 |
| MACD | -0.07 | 0.29 |
| Stochastic Oscillator | 22.93 | 70.18 |
Methode Electronics Inc supplier of custom-engineered solutions with sales, engineering, and manufacturing locations in North America, Europe, the Middle East, and Asia. It designs, engineers, and produces mechatronic products for Original Equipment Manufacturers (OEMs) utilizing a broad range of technologies for user interface, light-emitting diode (LED) lighting systems, power distribution, and sensor applications. The firm is organized into various business segments: Automotive, Industrial, Interface, and Medical. The Automotive segment, which generates maximum revenue, supplies electronic and electro-mechanical devices and related products to automobiles, including overhead and center consoles, hidden and ergonomic switches, insert molded components, LED-based lighting, and sensors.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.